Xifaxan sales

Xifaxan does not have a biosimilar risk because rifaximin is a small-molecule drug. Its principal competitive threat is an abbreviated new drug application, or ANDA, for generic rifaximin tablets. How much does Xifaxan generate in sales? Bausch reports Xifaxan as a major contributor to Salix revenue. Annual Sales of Xifaxan reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies. XIFAXAN ® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults. XIFAXAN ® (rifaximin) 550 mg tablets are indicated for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults. Annual Sales of Xifaxan, Rifacol, Fatroximin, Rifaximin reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies. Xifaxan® drove sales in the fourth quarter with 16% growth and was the primary contributor to segment growth for the full year. Key Takeaways: Rifaximin Market USD 73 million in sales were recorded in 2025, signalling broad clinician acceptance for hepatic encephalopathy and IBS‑D. The market is set to reach USD 110 million by 2034, buoyed by new therapeutic approvals and expanding generic capacity in Asia‑Pacific. Branded XIFAXAN sales are projected to continue a steep decline. The overall rifaximin market is now largely driven by generic competition, leading to significant price erosion. Alternative therapies for both hepatic encephalopathy and irritable bowel syndrome with diarrhea remain competitive. Frequently Asked Questions The Rifaximin market represents a specialized segment within the broader pharmaceutical landscape, primarily focused on the production, distribution, and clinical application of rifaximina semi synthetic, broad spectrum antibiotic derived from rifamycin. The indication push comes as Xifaxan is gaining market share, thanks to the field sales team—expanded by 250 reps last year—targeting primary care physicians, Papa said. Lotus anticipates that the FDA will grant final approval to Norwich's Rifaximin ANDA in the near term. According to Bausch Health, Xifaxan® generated sales of approximately US$2.2 billion in the United States in 2025¹, a significant portion of which is attributable to the IBS-D indication. BHC's fourth-quarter adjusted earnings and revenues beat estimates driven by Xifaxan. The guidance for 2025 is positive. The ruling ensures Bausch's XIFAXAN® retains market exclusivity until at least June 29, 2028, when Teva's generic enters the market. XIFAXAN® generated $1.2 billion in global sales in 2024, with IBS-D accounting for over 60% of U.S. prescriptions. Xifaxan (rifaximin) is used to treat traveler's diarrhea and irritable bowel syndrome with diarrhea. It is also used to prevent hepatic encephalopathy, a brain disorder that can occur due to severe liver disease. Xifaxan is a rifamycin which works by killing bacteria that causes infection. The most common form of Xifaxan is a 550mg tablet. BHC's fourth-quarter adjusted earnings and revenues beat estimates driven by Xifaxan. The guidance for 2025 is positive. Relistor and Trulance revenues were up 9% each. Xifaxan 550 mg tablets are indicated for the reduction in the risk of overt hepatic encephalopathy recurrence and the treatment of IBS-D in adults. RIFAXIMIN (ri FAX i men) treats diarrhea caused by bacteria. It may also be used to treat irritable bowel syndrome (IBS) with diarrhea. It can be used to prevent hepatic encephalopathy, a condition where the liver does not clear toxins from the body. It works by killing or preventing the growth of bacteria in your intestines that make toxins. It belongs to a group of medications called … Rifaximin, sold under the trade name Xifaxan among others, is an antibiotic used to treat traveler"s diarrhea, irritable bowel syndrome, and hepatic encephalopathy. Now that Valeant's $10 billion talks to sell its Salix unit to Takeda have reportedly fallen through, the company is taking matters into its own hands with a "significant" GI sales force … Get your Xifaxan 550 mg Tablets from HealthWarehouse, your trusted online pharmacy. We offer affordable healthcare products that get delivered right to your door. RIFAXIMIN (ri FAX i men) treats diarrhea caused by bacteria. It may also be used to treat irritable bowel syndrome (IBS) with diarrhea. It can be used to prevent hepatic encephalopathy, a condition where the liver does not clear toxins from the body. It works by killing or preventing the growth of bacteria in your intestines that make toxins. It belongs to a group of medications called … Compare generic Xifaxan (rifaximin) 550 mg prices from verified online pharmacies or local U.S. pharmacies. Free coupons for generic Xifaxan (rifaximin). Discounts up to 80% off the retail price. Cosmo Pharmaceuticals' antibiotic Aemcolo poses a serious threat to Bausch Health's top-selling antibiotic Xifaxan. (Bausch Health) Bausch Health has yet to fully recover from its tainted past … Yet, selling Salix would strip out one of Valeant's most attractive and best-selling assets, the irritable-bowel syndrome treatment Xifaxan (rifaximin). Although the drug has performed worse than expected this year — partly due to sales force turmoil — it still brought in $200 million in Q2 sales, more than any other drug in Valeant's … Save on Xifaxan (rifaximin) prescription medication with Blink Pharmacy. Same pills. Lower prices. No coupon req. XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults. RIFAXIMIN (ri FAX i men) treats diarrhea caused by bacteria. It may also be used to treat irritable bowel syndrome (IBS) with diarrhea. It can be used to prevent hepatic encephalopathy, a condition where the liver does not clear toxins from the body. It works by killing or preventing the growth of bacteria in your intestines that make toxins. It belongs to a group of medications called … RIFAXIMIN (ri FAX i men) treats diarrhea caused by bacteria. It may also be used to treat irritable bowel syndrome (IBS) with diarrhea. It can be used to prevent hepatic encephalopathy, a condition where the liver does not clear toxins from the body. It works by killing or preventing the growth of bacteria in your intestines that make toxins. It belongs to a group of medications called … Xifaxan supply disruptions are affecting patients nationwide. Check current availability, find pharmacies with stock near you, and explore your options. Xifaxan (rifaximin) is a prescription antibiotic used to treat irritable bowel syndrome with diarrhea (IBS-D), traveler's diarrhea caused by certain strains of E. coli, and to reduce the risk of recurrent hepatic encephalopathy in adults with liver disease. XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy recurrence and for the treatment of IBS-D in adults. See Important Safety Information and full Prescribing Information on website. XIFAXAN, Bausch Health's rifaximin product, is one of the largest gastrointestinal specialty drugs in the U.S. market. Its commercial base is concentrated in two approved indications: reduction in hepatic encephalopathy recurrence and treatment of irritable bowel syndrome with diarrhea. U.S. sales have continued to grow despite long-standing generic challenges, supported by high patient … Get the best price on Xifaxan at pharmacies near you with SingleCare. Save up to 80% with our Xifaxan coupons – with or without insurance! Sales growth was driven by Xifaxan® and Relistor®, partially offset by net pricing pressures for Trulance® and certain non-promoted products. International Segment International segment reported revenues were $265 million for the first quarter of 2024, compared with $247 million for the first quarter of 2023, an increase of $18 million, or 7%. Our Take on BHC's Q3 Results Bausch's third-quarter results were encouraging, with sales and earnings beating estimates. The increase in guidance was another positive. The Salix business maintained its momentum on the back of Xifaxan, which witnessed strong growth in underlying demand. The guidance for 2025 is also encouraging. The Salix business maintained its momentum on the back of Xifaxan, which witnessed strong growth in underlying demand. Bausch Health's wholly-owned subsidiary, 1261229 B.C. LTD., entered into a financing commitment with a third-party lender to provide a senior secured credit facility of up to $700 million. The most common adverse reactions in clinical studies of XIFAXAN for hepatic encephalopathy included peripheral edema, constipation, and nausea, while for irritable bowel syndrome with diarrhea … The U.S. Supreme Court turned away on Monday a bid by Alvogen's subsidiary Norwich Pharmaceuticals to sell a generic version of Canada-based Bausch Health's blockbuster diarrhea drug Xifaxan. Clinical briefing on the Xifaxan shortage for providers: supply chain data, prescribing alternatives, and patient access strategies for 2026. The Rifaximin market was valued at $2.1 billion in 2025 and is projected to reach $5.4 billion by 2034, growing at a CAGR of 11.4%.